Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)

Trial Details

NCT ID
NCT07228832
Phase
PHASE3
Sponsor
Summit Therapeutics
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Drug: Ivonescimab Injection
  • Drug: Bevacizumab Injection
Locations (sample)
  • Goodyear, Arizona, United States|33.43532,-112.35821
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Cerritos, California, United States|33.85835,-118.06479
  • Corona, California, United States|33.87529,-117.56644
  • Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

  • ECOG performance status score of 0 or 1
  • Expected life expectancy ≥ 6 months
  • Patients with histologically or cytologically confirmed metastatic CRC
  • No prior systemic therapy for metastatic CRC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →